Dec. 3 at 5:00 PM
$CRDL Why ARCHER Attracts Big Pharma
CardiolRx showed a –9.2 g drop in LV mass in 12 weeks in acute myocarditis — a fast, dangerous disease where permanent damage can occur within weeks. Speed matters, and nothing else works this fast.
Compare to blockbuster drugs that also reduce LV mass:
• Tirzepatide: –11 g in 52 weeks,
$1–3B HF revenue
• Jardiance: –5 g in 26 weeks,
$8B yearly
• Entresto: –11.3 g in 36 weeks,
$6–8B yearly
Key insight:
➡️ CardiolRx delivers similar heart-repair effects 2–4× faster than these multi-billion-dollar medicines.
In myocarditis, that speed can mean full recovery instead of long-term heart failure.
Why ARCHER fits big pharma perfectly:
• Blockbuster-level structural improvement
• Faster effect than existing HF drugs
• Disease with no approved therapy
• Safety equal to placebo — extremely rare
Bottom line:
Blockbuster-class heart recovery in 12 weeks, zero competition. Exactly the profile big pharma wants.
